15. Inclusion body myositis Clinical trials / Disease details
Clinical trials : 42 / Drugs : 33 - (DrugBank : 11) / Drug target genes : 12 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03440034 (ClinicalTrials.gov) | May 22, 2018 | 14/11/2017 | Study of Pioglitazone in Sporadic Inclusion Body Myositis | An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis | Myositis;Inclusion Body Myositis;Muscular Diseases;Musculoskeletal Disease;Neuromuscular Diseases;Nervous System Diseases | Drug: Pioglitazone | Johns Hopkins University | NULL | Completed | 50 Years | N/A | All | 19 | Phase 1 | United States |